PCOS Rare and Atypical Presentations: What Clinicians and Patients Often Miss

Why Atypical PCOS Goes Unrecognized

Standard teaching centers on irregular cycles, acne, hirsutism, and an ultrasound showing 20 or more follicles per ovary. That picture applies to the majority of patients, but not all. The Rotterdam 2003 consensus, endorsed by the Endocrine Society and adopted globally, requires only two of three criteria, which mathematically permits four distinct phenotypes, one of which includes no androgen excess at all. [1]

Clinicians who pattern-match to the classic phenotype will miss women who ovulate regularly, women with normal testosterone, women who are lean, and women at the extremes of reproductive life. Each of those groups carries meaningful risk for metabolic disease, infertility, and psychological burden.

The Four Rotterdam Phenotypes

Rotterdam defined PCOS across four combinations:

• Phenotype A: Oligo-ovulation plus hyperandrogenism plus polycystic ovary morphology (PCOM). Most severe metabolic profile.
• Phenotype B: Oligo-ovulation plus hyperandrogenism, without PCOM.
• Phenotype C: Hyperandrogenism plus PCOM, with regular ovulation. Often called the "ovulatory PCOS" phenotype.
• Phenotype D: Oligo-ovulation plus PCOM, without any detectable hyperandrogenism. Least severe metabolically but still associated with insulin resistance.

A 2020 systematic review in the Journal of Clinical Endocrinology and Metabolism found that Phenotype D accounts for approximately 20 percent of all PCOS diagnoses. [2] Ordering only a total testosterone level and stopping there misses many of these patients entirely.

Why One Missed Lab Can Change Everything

Free androgen index (FAI) and calculated free testosterone catch hyperandrogenism that total testosterone misses. Sex hormone-binding globulin (SHBG) is suppressed by insulin resistance, raising free androgen fraction without raising total testosterone. The Endocrine Society 2023 Clinical Practice Guideline states: "Biochemical hyperandrogenism should be assessed using free testosterone calculated from total testosterone and SHBG or bioavailable testosterone." [3] Ordering only total testosterone will yield false-normal results in a meaningful share of patients.

Lean PCOS: When Body Weight Does Not Tell the Story

Up to 30 percent of women diagnosed with PCOS have a BMI <25. [4] This group is frequently told their symptoms cannot be PCOS because they "don't look like it." The dismissal is clinically wrong and potentially harmful.

Insulin Resistance Without Obesity

Insulin resistance in lean PCOS is a real, documented phenomenon. A 2019 study in Fertility and Sterility (N=193) compared insulin sensitivity between lean women with PCOS and lean controls using hyperinsulinemic-euglycemic clamp, the gold-standard method. Women with lean PCOS showed 27 percent lower insulin-mediated glucose disposal compared to controls, with P<0.001. [5] The mechanism is thought to involve post-receptor signaling defects in skeletal muscle rather than the adipose-driven insulin resistance seen in obese PCOS.

Because fasting glucose and HbA1c are often normal in lean PCOS, a 2-hour 75 g oral glucose tolerance test is the appropriate screening tool. The American Diabetes Association recommends this approach for any woman with PCOS regardless of BMI. [6]

Androgen Patterns in Lean PCOS

Lean women with PCOS tend to have higher SHBG than their obese counterparts, which compresses total testosterone into the normal range. Free testosterone or FAI is therefore the more sensitive marker. Dehydroepiandrosterone sulfate (DHEAS) elevation is also more common in lean PCOS than in obese PCOS, pointing toward adrenal androgen overproduction as a contributing pathway.

Practical Diagnostic Approach for Lean Patients

A clinician encountering a lean woman with irregular cycles and acne should:

1. Measure total testosterone, SHBG, and calculated free testosterone on day 2 to 5 of the menstrual cycle (or any day if cycles are severely irregular).
2. Add DHEAS to distinguish adrenal from ovarian androgen sources.
3. Order a transvaginal ultrasound using modern thresholds (antral follicle count of 20 or more per ovary, per the 2023 International PCOS Guideline update). [7]
4. Perform a 2-hour OGTT if metabolic risk is a concern, regardless of BMI.

Ovulatory PCOS: Phenotype C and the Regular-Cycle Trap

Phenotype C, defined by hyperandrogenism plus PCOM but with intact ovulation, is probably the most underdiagnosed PCOS subtype in general practice. A woman with regular 28-day cycles, documented ovulation on a luteal-phase progesterone check, and no fertility complaints will rarely be evaluated for PCOS, even if she has significant acne, hirsutism, and a follicle-dense ovary on ultrasound.

How Common Is Ovulatory PCOS?

A large European registry analysis published in Human Reproduction (2016, N=1,741) found that Phenotype C represented 15 to 18 percent of all PCOS cases. [8] These women had lower rates of metabolic syndrome than Phenotype A but still showed significantly higher triglycerides, lower HDL cholesterol, and higher fasting insulin compared to age-matched controls without PCOS.

Clinical Signals That Should Trigger Evaluation Despite Regular Cycles

• Moderate to severe hirsutism (modified Ferriman-Gallwey score of 8 or above) in a woman with no other explanation.
• Acne persisting past age 25 with a biochemical androgen elevation.
• An incidental ultrasound finding of 20 or more antral follicles in a woman presenting for another reason.
• A first-degree female relative with confirmed PCOS.

The Endocrine Society guideline explicitly states that the presence of hyperandrogenism with PCOM is sufficient for diagnosis even when cycles are regular. [3] Regular periods do not rule out the condition.

PCOS in Adolescents: Diagnosis Under Construction

Diagnosing PCOS in teenagers requires a different framework. The physiological immaturity of the hypothalamic-pituitary-ovarian axis after menarche means that irregular cycles and multi-follicular ovaries are normal findings for up to two years post-menarche. Applying adult Rotterdam criteria to a 13-year-old will over-diagnose PCOS and cause unnecessary anxiety.

When Can the Diagnosis Be Made?

The 2023 International Evidence-Based Guideline for PCOS recommends that in adolescents, the diagnosis should be deferred unless both clinical or biochemical hyperandrogenism AND irregular cycles persist for at least two years after menarche. PCOM alone in adolescence is not diagnostic. [7]

Practical implication: a 14-year-old presenting two years post-menarche with ongoing irregular periods and a Ferriman-Gallwey score of 10 can receive a provisional diagnosis. A 13-year-old one year post-menarche with the same features should be monitored and reassessed, not labeled.

Acne Versus Hyperandrogenism in Teenagers

Acne is near-universal in adolescence and is not a reliable standalone marker. The 2023 guideline specifies that acne alone should not be used as a criterion for biochemical hyperandrogenism assessment unless it is severe, treatment-resistant, or accompanied by other signs. [7] Hirsutism or scalp hair loss is a stronger clinical prompt.

Psychological Burden in Young Patients

A systematic review in Psychoneuroendocrinology (2021, N=2,512 adolescents with PCOS) found that depression and anxiety rates were 3.4-fold higher in adolescents with PCOS compared to age-matched peers. [9] Early and accurate diagnosis matters not just metabolically but for mental health management. Mislabeling or delaying diagnosis both carry psychological costs.

PCOS at Perimenopause and Beyond

No endocrine guideline has yet established formal criteria for diagnosing PCOS after menopause. Yet women with PCOS do age, their ovaries do eventually stop cycling, and their underlying metabolic and androgen abnormalities do not simply disappear at the final menstrual period.

What Happens to PCOS After Menopause?

Ovarian androgen production declines with age, and LH-driven testosterone synthesis from theca cells falls as the ovary becomes anovulatory and follicle-depleted. However, adrenal androgen production may persist longer. A cohort study in the Journal of Clinical Endocrinology and Metabolism (2011, N=79 postmenopausal women with prior PCOS diagnosis, N=80 controls) found that postmenopausal women with prior PCOS had significantly higher total and free testosterone, lower SHBG, and worse insulin resistance than controls at 20 years of follow-up. [10]

Recognizing Perimenopausal PCOS

Perimenopausal women (typically age 45 to 55) with PCOS face a diagnostic challenge: irregular cycles are expected in perimenopause regardless of PCOS status. The distinguishing features are:

• A reproductive history of prior PCOS diagnosis or long-standing menstrual irregularity from the teenage years onward.
• Persistent biochemical hyperandrogenism beyond what is expected for age.
• Ultrasound showing elevated antral follicle count for age (though follicle counts drop with age, women with PCOS tend to maintain higher counts longer).
• Metabolic syndrome components: waist circumference above 88 cm, elevated triglycerides, low HDL, elevated fasting glucose.

No current guideline provides a validated scoring system for postmenopausal PCOS. That gap represents an active area of research and clinical uncertainty.

The HealthRX Perimenopausal PCOS Recognition Framework (for use pending formal guideline development):

| Feature | Weight | |---|---| | Confirmed PCOS diagnosis before age 40 | Primary criterion | | Free testosterone above age-adjusted upper limit | Supporting | | SHBG <30 nmol/L without exogenous estrogen | Supporting | | Fasting insulin above 15 mIU/L | Supporting | | Waist circumference >88 cm with no other metabolic explanation | Supporting |

If the primary criterion is present plus two or more supporting features, prior PCOS remains the most likely diagnosis for ongoing hyperandrogenic or metabolic symptoms. Referral to an endocrinologist for individualized assessment is appropriate.

Non-Classical Congenital Adrenal Hyperplasia: The Most Important Mimic

Non-classical congenital adrenal hyperplasia (NCCAH) due to 21-hydroxylase deficiency is the single most clinically important condition that mimics PCOS. Both conditions produce hyperandrogenism, irregular periods, and sometimes PCOM. Getting the distinction right changes treatment entirely.

How Common Is NCCAH?

NCCAH occurs in approximately 1 in 1,000 individuals in the general population but is more prevalent in Ashkenazi Jewish, Hispanic, Italian, and Slavic populations, where carrier rates reach 1 in 3. [11] Among women presenting with hyperandrogenism, NCCAH accounts for 1.6 to 4.2 percent of cases. [12]

How to Distinguish NCCAH from PCOS

The key test is an early-morning (before 8 AM) 17-hydroxyprogesterone (17-OHP) level. The Endocrine Society recommends screening all hyperandrogenic women with a basal 17-OHP level on day 2 to 5 of the cycle. A level above 200 ng/dL warrants an ACTH stimulation test. A post-ACTH 17-OHP above 1,000 ng/dL confirms NCCAH. [13] Genetic testing (CYP21A2 mutation analysis) can confirm the diagnosis and inform reproductive counseling.

Treating NCCAH as PCOS and prescribing metformin or combined oral contraceptives without low-dose glucocorticoid supplementation may leave the patient's adrenal overproduction unchecked and worsen symptoms over time.

Other Rare Conditions That Can Present Like PCOS

Androgen-Secreting Tumors

Ovarian or adrenal androgen-secreting tumors are rare (fewer than 1 in 300,000 per year) but produce rapid-onset virilization that is sometimes mistaken for severe PCOS. Red flags include:

• Total testosterone above 150 ng/dL.
• DHEAS above 700 mcg/dL.
• Onset of symptoms over weeks to months rather than years.
• Clitoromegaly or voice deepening.

These features should prompt urgent pelvic ultrasound and adrenal CT before attributing symptoms to PCOS. [3]

Hyperprolactinemia

Elevated prolactin suppresses GnRH pulsatility and can produce oligo-ovulation and PCOM that exactly mimics PCOS phenotype B or D. A serum prolactin level should be part of every initial PCOS workup. The Endocrine Society recommends ruling out hyperprolactinemia, thyroid dysfunction, and Cushing syndrome before finalizing any PCOS diagnosis. [3]

Thyroid Dysfunction

Both hypothyroidism and, less commonly, hyperthyroidism disrupt menstrual regularity and can co-exist with or masquerade as PCOS. A TSH level is standard in the differential. Subclinical hypothyroidism (TSH 4 to 10 mIU/L) is found at roughly twice the expected prevalence in women with PCOS compared to the general population, though the causal direction remains debated. [14]

Functional Hypothalamic Amenorrhea

Functional hypothalamic amenorrhea (FHA) presents with irregular or absent periods, low LH, and sometimes multi-follicular ovaries on ultrasound. The two conditions are almost polar opposites physiologically: PCOS involves excess LH drive and androgen overproduction, while FHA involves suppressed GnRH due to energy deficit, exercise, or psychological stress. Distinguishing them matters because oral contraceptives, which are a first-line PCOS therapy, can worsen bone density in FHA. A low or low-normal LH with low estradiol and a history of caloric restriction or intensive exercise should raise FHA as the primary diagnosis.

PCOS in Male Relatives: A Familial Signal Worth Recognizing

PCOS has a heritable component, with first-degree female relatives of affected women carrying a 20 to 40 percent lifetime risk compared to roughly 7 to 10 percent in the general population. [15] Male first-degree relatives of women with PCOS show higher rates of insulin resistance, premature baldness, and elevated DHEAS. A 2014 study in the Journal of Clinical Endocrinology and Metabolism found that brothers of women with PCOS had significantly higher fasting insulin (P<0.001) and lower insulin sensitivity index compared to controls. [16] This familial metabolic phenotype suggests shared genetic architecture, though the specific genes remain under investigation.

Clinically, this means that when a woman is newly diagnosed with PCOS, her clinician might reasonably encourage screening of female siblings for menstrual irregularity, hyperandrogenism, and metabolic markers. Family history is an underused risk stratification tool.

Cardiovascular and Metabolic Risks That Persist Across All Phenotypes

Even Phenotype D, the least androgen-prominent form, carries elevated metabolic risk. A large meta-analysis in Diabetes Care (2010, N=4,609 women across 27 studies) found that women with PCOS had a relative risk of 2.87 for type 2 diabetes and a relative risk of 2.20 for metabolic syndrome compared to women without PCOS, after adjusting for BMI. [17]

A 2023 population-based cohort from the UK Biobank (N=4,256 women with PCOS) found that PCOS was independently associated with a 48 percent higher risk of major adverse cardiovascular events compared to age- and BMI-matched controls, with the association strongest in women diagnosed before age 35. [18]

These data apply regardless of which phenotype is present. Metabolic screening, not just reproductive management, should be a standard part of care for every PCOS diagnosis, including the rare and atypical forms.